Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $41.56 Consensus Target Price from Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have earned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $41.5556.

Several brokerages recently commented on CLDX. Mizuho started coverage on shares of Celldex Therapeutics in a research report on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. Finally, Barclays upped their price target on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a research note on Wednesday, December 17th.

Celldex Therapeutics Stock Up 5.2%

Shares of NASDAQ:CLDX opened at $23.76 on Friday. The company has a market cap of $1.58 billion, a P/E ratio of -7.03 and a beta of 1.24. The business has a fifty day simple moving average of $26.39 and a 200-day simple moving average of $25.21. Celldex Therapeutics has a 52 week low of $14.40 and a 52 week high of $30.50.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.13). Celldex Therapeutics had a negative return on equity of 33.22% and a negative net margin of 3,446.88%. Sell-side analysts expect that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Celldex Therapeutics news, insider Richard M. Wright sold 49,298 shares of Celldex Therapeutics stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the transaction, the insider directly owned 20,833 shares of the company’s stock, valued at $499,992. The trade was a 70.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.40% of the company’s stock.

Institutional Trading of Celldex Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd purchased a new stake in shares of Celldex Therapeutics in the third quarter worth about $26,000. Nisa Investment Advisors LLC boosted its holdings in Celldex Therapeutics by 171.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 881 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Celldex Therapeutics in the third quarter valued at approximately $42,000. Russell Investments Group Ltd. raised its stake in shares of Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of Celldex Therapeutics during the third quarter worth $63,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.